Ionis Q3 2023 Earnings Report
Key Takeaways
Ionis Pharmaceuticals reported Q3 2023 financial results, with total revenue of $144 million. The company is on track for potential U.S. approval of eplontersen and reported positive data from the olezarsen Phase 3 Balance study. Strategic investments in eplontersen, olezarsen, and donidalorsen contributed to increased operating expenses.
Total revenue reached $144 million, driven by commercial and R&D revenues.
Eplontersen is under regulatory review in the EU and Canada, with potential U.S. approval in December 2023.
Positive data was reported from the olezarsen Phase 3 Balance study, positioning it for potential commercial launch.
Advanced zilganersen into Phase 3 development for Alexander disease.
Ionis
Ionis
Ionis Revenue by Segment
Forward Guidance
Ionis is on track to achieve its 2023 financial guidance, supported by a strong financial foundation, significant royalty revenue from SPINRAZA, and substantial R&D revenue from multiple partners. The company is well-positioned to invest in key priorities to drive future positive cash flow.
Positive Outlook
- Potential U.S. eplontersen ATTRv-PN approval next month followed closely by launch
- Strong financial foundation with more than $2B in cash
- Significant royalty revenue with SPINRAZA
- Substantial and sustained R&D revenue from multiple partners
- Advancing go-to-market activities
Revenue & Expenses
Visualization of income flow from segment revenue to net income